2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow PF 04217329: new trials by email Literature Review of PF 04217329 trials Research Report on PF 04217329
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329 PF-04217329, latanoprost vehicle, latanoprost - Glaucoma, Open-Angle, Ocular Hypertension | Phase 2 | Completed | Pfizer | 31 | 2010-01-01 | 2021-05-03 |
| Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure. PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose - Primary Open-Angle Glaucoma, Ocular Hypertension | Phase 2 | Completed | Pfizer | 318 | 2007-12-11 | 2021-04-30 |
Glaucoma, Open-Angle (2) · Ocular Hypertension (2)
Pfizer (2)
United States (2)